Business Insights, PHARMACY MARKET

Combatting Future Viral Threats with Vaccine Advances

February 3, 2023

Combatting Future Viral
Since the beginning of the COVID-19 pandemic, pharmaceutical organizations have experienced major changes, a prime example of which has been the rising requirement for collaborations on multiple different fronts across the industry.

Spotlight

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals $NBY is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX™ family of products, led by AVENOVA™ for the eye care market, NEUTROPHASE® for wound care, and CELLERX™ for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million.

OTHER WHITEPAPERS
news image

Pharma R&D Annual Review 2022 Navigating the Landscape

whitePaper | May 7, 2022

Citeline, Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.

Read More
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Read More
news image

10 Tips on Selecting Cartridge Dust Collection Equipment for Tablet Presses

whitePaper | December 28, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical.

Read More
news image

Ultimate Pharma Messaging Guidebook

whitePaper | March 10, 2023

This pharma messaging guidebook features 20 proven cognitive science techniques that can be used to optimize pharmaceutical claims and messages.

Read More
news image

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More

Spotlight

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals $NBY is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX™ family of products, led by AVENOVA™ for the eye care market, NEUTROPHASE® for wound care, and CELLERX™ for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million.

Events